These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32608372)

  • 1. Innovative therapies for malignant brain tumors: the road to a tailored cure.
    Giotta Lucifero A; Luzzi S; Brambilla I; Trabatti C; Mosconi M; Savasta S; Foiadelli T
    Acta Biomed; 2020 Jun; 91(7-S):5-17. PubMed ID: 32608372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).
    Giotta Lucifero A; Luzzi S
    Brain Sci; 2021 Mar; 11(3):. PubMed ID: 33803885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges.
    Luzzi S; Giotta Lucifero A; Brambilla I; Magistrali M; Mosconi M; Savasta S; Foiadelli T
    Acta Biomed; 2020 Jun; 91(7-S):18-31. PubMed ID: 32608373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immune-based technologies for high-grade gliomas.
    Giotta Lucifero A; Luzzi S
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):957-980. PubMed ID: 35924820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas.
    Giotta Lucifero A; Luzzi S; Brambilla I; Schena L; Mosconi M; Foiadelli T; Savasta S
    Acta Biomed; 2020 Jun; 91(7-S):61-78. PubMed ID: 32608376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.
    Maxwell R; Luksik AS; Garzon-Muvdi T; Lim M
    Curr Neurol Neurosci Rep; 2017 Jun; 17(6):50. PubMed ID: 28488122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for recurrent high-grade gliomas.
    Birk HS; Han SJ; Butowski NA
    CNS Oncol; 2017 Jan; 6(1):61-70. PubMed ID: 28001091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
    Lau D; Magill ST; Aghi MK
    Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies for glioblastoma.
    Thomas AA; Brennan CW; DeAngelis LM; Omuro AM
    JAMA Neurol; 2014 Nov; 71(11):1437-44. PubMed ID: 25244650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune and viral therapies for malignant primary brain tumors.
    Gardeck AM; Sheehan J; Low WC
    Expert Opin Biol Ther; 2017 Apr; 17(4):457-474. PubMed ID: 28274139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
    Kubo O; Takakura K
    Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel chemotherapeutics and other therapies for treating high-grade glioma.
    Kang JH; Adamson C
    Expert Opin Investig Drugs; 2015; 24(10):1361-79. PubMed ID: 26289791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontiers in targeting glioma stem cells.
    Frosina G
    Eur J Cancer; 2011 Mar; 47(4):496-507. PubMed ID: 21185169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single vs. combination immunotherapeutic strategies for glioma.
    Chandran M; Candolfi M; Shah D; Mineharu Y; Yadav VN; Koschmann C; Asad AS; Lowenstein PR; Castro MG
    Expert Opin Biol Ther; 2017 May; 17(5):543-554. PubMed ID: 28286975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor-Targeted Glial Brain Tumor Therapies.
    Sharma P; Debinski W
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30366424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer stem cells and malignant gliomas. From pathophysiology to targeted molecular therapy.
    Florian IS; Tomuleasa C; Soritau O; Timis T; Ioani H; Irimie A; Kacso G
    J BUON; 2011; 16(1):16-23. PubMed ID: 21674845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.